Starting in 2010, the epidermal growth factor receptor (EGFR) kinase inhibitor drugs erlotinib and gefitinib were introduced into routine clinical use in NZ for the treatment of advanced lung cancer [4]. The gene discussed is EGFR; the disease is lung carcinoma.